查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1405892

前列腺癌診斷市場規模、佔有率、趨勢分析報告：按測試類型、類型、最終用途、地區、細分市場預測，2024-2030 年

Prostate Cancer Diagnostics Market Size, Share & Trends Analysis Report By Test Type (Preliminary Tests, Confirmatory Tests), By Type (Adenocarcinoma, Interstitial Cell Carcinoma, Other), By End Use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 152 Pages | 商品交期: 2-10個工作天內

價格

前列腺癌診斷市場的成長和趨勢：

Grand View Research, Inc.最新報告顯示，2030年全球前列腺癌診斷市場規模預計將達到131.6億美元，2024年至2030年複合年成長率為6.4%。

政府的支持措施、全球疾病盛行率的增加、前列腺癌盛行率的增加以及確證診斷測試的技術進步是該市場的主要驅動力。

政府採取更多有利舉措來加強以有效診斷和治療為重點的研究，預計將在預測期內推動市場成長。例如，國家癌症研究所發起了一項題為「非裔男性前列腺癌研究：定義遺傳學、腫瘤標記和社會壓力的作用」（RESPOND）的研究。這項研究是調查與非裔美國男性前列腺癌相關的非生物和生物因素的最大合作研究。該計畫由美國少數族裔健康研究所、NCI 和健康差異研究所與前列腺癌基金會合作發起，資金達 2,600 萬美元。

諾福克大學、酵母安格利亞研究與發展中心和諾維奇大學醫院開發了一種非侵入性尿液檢查，有助於識別診斷後五年內需要治療的可能性降低八倍的男性。預計此類技術進步也將在不久的將來影響市場潛力。

此外，卡羅林斯卡學院和瑞典皇家理工學院的研究人員得出結論，利用人工智慧進行空間轉錄組學可以幫助早期發現前列腺癌，從而改善臨床診斷和治療。空間轉錄組學是一種通常結合活性基因及其組織學定量分析的技術，可用於有效的疾病診斷。

前列腺癌診斷市場報告亮點

  • 到 2023 年，確認測試將佔據最大的市場佔有率。該細分市場的市場佔有率最大，達 66.4%。確認性測試包括 PCA3 測試、超音波(TRUS) 和受影響區域的切片檢查。
  • 根據最終用途，市場分為醫院、門診病人設施、居家醫療以及研究和製造。 2023年，門診病人設施領域佔據市場主導地位。透過獲得醫療執照和累積經驗，門診設施徹底改變了更舒適的諮詢和治療系統。
  • 由於患病率不斷上升以及政府措施不斷增多，北美地區佔據了最大的市場佔有率。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章前列腺癌診斷市場變數、趨勢和範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場抑制因素分析
  • 前列腺癌診斷市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章前列腺癌診斷市場：測試類型的估計和趨勢分析

  • 2023 年和 2030 年測試類型市場佔有率
  • 細分儀表板
  • 按測試類型分類的全球前列腺癌診斷市場展望
  • 2018-2030 年市場規模、預測與趨勢分析如下
    • 初步測試
    • 確認檢查

第5章前列腺癌診斷市場：類型估計和趨勢分析

  • 類型市場佔有率，2023 年和 2030 年
  • 細分儀表板
  • 按類型分類的全球前列腺癌診斷市場展望
  • 2018-2030 年市場規模、預測與趨勢分析如下
    • 腺癌
    • 間質細胞癌
    • 其他

第6章前列腺癌診斷市場：最終用途估計與趨勢分析

  • 2023 年及 2030 年最終用途市場佔有率
  • 細分儀表板
  • 按最終用途分類的全球前列腺癌診斷市場展望
  • 2018-2030 年市場規模、預測與趨勢分析如下
    • 醫院
    • 門診設施
    • 居家護理
    • 研究/製造

第7章前列腺癌診斷市場：區域估計和趨勢分析

  • 2023 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 全球區域市場概況
  • 2018-2030年市場規模及預測趨勢分析：
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章競爭形勢

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭分類
  • 供應商形勢
    • List of key distributors and channel partners
    • Key customers
    • Key company market share analysis, 2023
    • MDx Health
    • Myriad Genetics, Inc.
    • Abbott Laboratories
    • F. Hoffman-La Roche AG
    • Bayer AG
    • Siemens Healthcare GmbH
    • OPKO Health, Inc.
    • Genomic Health.
    • Pfizer Inc.
Product Code: GVR-2-68038-548-9

Prostate Cancer Diagnostics Market Growth & Trends:

The global prostate cancer diagnostics market size is expected to reach USD 13.16 billion by 2030, expanding at a CAGR of 6.4% from 2024 to 2030,according to a new report by Grand View Research, Inc. Supportive government initiatives, increasing disease prevalence across the globe, and a rise in the prevalence of prostate cancer coupled with technological advancements in confirmatory diagnostic tests are the major drivers for this market.

A rise in favorable government initiatives to enhance research associated with a focus on effective diagnosis and treatment is expected to boost market growth during the forecast period. For instance, the National Cancer Institute initiated the study titled 'Research on Prostate Cancer in Men of African Ancestry: Defining the Roles of Genetics, Tumor Markers, and Social Stress' (RESPOND). This study is the largest collaboration to research the non-biological and biological factors that are associated with prostate cancer in African-American men. It was launched by the National Institute on Minority Health and NCI and Health Disparities in collaboration with the Prostate Cancer Foundation with a funding of USD 26.0 million.

Researchers from the University of Norfolk and East Anglia along with Norwich University Hospital developed a non-invasive urine test that helps in identifying men that are up to 8 times less likely to need a treatment procedure within 5 years of diagnosis. Technological advancements such as these are also anticipated to impact market potential in the near future.

Additionally, researchers at Karolinska and KTH Institute concluded that the use of artificial intelligence in spatial transcriptomics can aid in the early detection of prostate cancer, thereby, improving clinical diagnosis and treatment. Spatial transcriptomics is a method that usually combines quantitative analysis of active genes and their histology and can aid in effective disease diagnosis.

Prostate Cancer Diagnostics Market Report Highlights:

  • Confirmatory tests held the largest market share in 2023. The segment holds largest market share by 66.4%. Confirmatory tests include the PCA3 test, Transrectal Ultrasound (TRUS), and biopsy of the affected portion
  • Based on end use, the market is segmented into hospitals, outpatient facilities, home care, and research & manufacturing. In 2023, the Outpatient Facilities segment dominated the market. Outpatient Facilities have revolutionized and developed more comfortable consulting and treatment systems with the acquisition and experience of the licensed physician
  • The North American region holds the largest market share owing to rising prevalence and the rise in government initiatives to enhance diagnosis

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Test Type
    • 1.2.2. Type
    • 1.2.3. End Use
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Test Type
    • 2.2.2. Type
    • 2.2.3. End Use
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Prostate Cancer Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of prostate cancer
      • 3.2.1.2. Increasing global geriatric population
      • 3.2.1.3. Technological advancements in the field of cancer diagnostics
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost of diagnostics
  • 3.3. Prostate Cancer Diagnostics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Prostate Cancer Diagnostics Market: Test Type Estimates & Trend Analysis

  • 4.1. Test Type Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Prostate Cancer Diagnostics Market by Test Type Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Preliminary Tests
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.2. PSA Tests
      • 4.4.1.2.1 Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.3. Free PSA Test
      • 4.4.1.3.1 Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.4. Total PSA Test
      • 4.4.1.4.1 Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.5. Other Preliminary Tests
      • 4.4.1.5.1 Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Confirmatory Tests
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.2. Pca3 Test
      • 4.4.2.2.1 Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.3. Trans-Rectal Ultrasound
      • 4.4.2.3.1 Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.4. Biopsy Test
      • 4.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Prostate Cancer Diagnostics Market: Type Estimates & Trend Analysis

  • 5.1. Type Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Prostate Cancer Diagnostics Market by Type Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Adenocarcinoma
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Interstitial Cell Carcinoma
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. Other
      • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Prostate Cancer Diagnostics Market: End Use Estimates & Trend Analysis

  • 6.1. End-use Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Prostate Cancer Diagnostics Market by End Use Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Hospitals
      • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Outpatient Facilities
      • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Home Care
      • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Research & Manufacturing
      • 6.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Prostate Cancer Diagnostics Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2023 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.5. North America
    • 7.5.1. U.S.
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. Canada
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Europe
    • 7.6.1. UK
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Germany
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. France
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.4. Italy
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework/ reimbursement structure
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.5. Spain
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework/ reimbursement structure
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.6. Norway
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework/ reimbursement structure
      • 7.6.6.3. Competitive scenario
      • 7.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.7. Sweden
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Regulatory framework/ reimbursement structure
      • 7.6.7.3. Competitive scenario
      • 7.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.8. Denmark
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Regulatory framework/ reimbursement structure
      • 7.6.8.3. Competitive scenario
      • 7.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Japan
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. China
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. India
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Australia
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.5. South Korea
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Regulatory framework/ reimbursement structure
      • 7.7.5.3. Competitive scenario
      • 7.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.6. Thailand
      • 7.7.6.1. Key country dynamics
      • 7.7.6.2. Regulatory framework/ reimbursement structure
      • 7.7.6.3. Competitive scenario
      • 7.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Brazil
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Regulatory framework/ reimbursement structure
      • 7.8.1.3. Competitive scenario
      • 7.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.2. Mexico
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework/ reimbursement structure
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.3. Argentina
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Regulatory framework/ reimbursement structure
      • 7.8.3.3. Competitive scenario
      • 7.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9. MEA
    • 7.9.1. South Africa
      • 7.9.1.1. Key country dynamics
      • 7.9.1.2. Regulatory framework/ reimbursement structure
      • 7.9.1.3. Competitive scenario
      • 7.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.2. Saudi Arabia
      • 7.9.2.1. Key country dynamics
      • 7.9.2.2. Regulatory framework/ reimbursement structure
      • 7.9.2.3. Competitive scenario
      • 7.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.3. UAE
      • 7.9.3.1. Key country dynamics
      • 7.9.3.2. Regulatory framework/ reimbursement structure
      • 7.9.3.3. Competitive scenario
      • 7.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.4. Kuwait
      • 7.9.4.1. Key country dynamics
      • 7.9.4.2. Regulatory framework/ reimbursement structure
      • 7.9.4.3. Competitive scenario
      • 7.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2023
    • 8.3.4. MDx Health
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Test Type benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Myriad Genetics, Inc.
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Test Type benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Abbott Laboratories
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Test Type benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. F. Hoffman-La Roche AG
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Test Type benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Bayer AG
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Test Type benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Siemens Healthcare GmbH
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Test Type benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. OPKO Health, Inc.
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Test Type benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Genomic Health.
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Test Type benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Pfizer Inc.
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Test Type benchmarking
      • 8.3.12.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America Prostate Cancer Diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 4 North America Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 5 North America Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 6 U.S. Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 7 U.S. Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 8 U.S. Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 9 Canada Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 10 Canada Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 11 Canada Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 12 Europe Prostate Cancer Diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 13 Europe Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 14 Europe Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 15 Europe Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 16 Germany Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 17 Germany Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 18 Germany Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 19 UK Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 20 UK Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 21 UK Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 22 France Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 23 France Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 24 France Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 25 Italy Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 26 Italy Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 27 Italy Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 28 Spain Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 29 Spain Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 30 Spain Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 31 Denmark Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 32 Denmark Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 33 Denmark Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 34 Sweden Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 35 Sweden Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 36 Sweden Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 37 Norway Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 38 Norway Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 39 Norway Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific Prostate Cancer Diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 44 China Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 45 China Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 46 China Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 47 Japan Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 48 Japan Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 49 Japan Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 50 India Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 51 India Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 52 India Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 53 South Korea Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 54 South Korea Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 55 South Korea Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 56 Australia Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 57 Australia Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 58 Australia Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 59 Thailand Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 60 Thailand Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 61 Thailand Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 62 Latin America Prostate Cancer Diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 63 Latin America Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 64 Latin America Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 65 Latin America Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 66 Brazil Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 67 Brazil Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 68 Brazil Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 69 Mexico Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 70 Mexico Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 71 Mexico Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 72 Argentina Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 73 Argentina Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 74 Argentina Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 75 MEA Prostate Cancer Diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 76 MEA Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 77 MEA Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 78 MEA Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 79 South Africa Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 80 South Africa Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 81 South Africa Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 85 UAE Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 86 UAE Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 87 UAE Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 88 Kuwait Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 89 Kuwait Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 90 Kuwait Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Prostate Cancer Diagnostics market: market outlook
  • Fig. 14 Prostate Cancer Diagnostics competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Prostate Cancer Diagnostics market driver impact
  • Fig. 20 Prostate Cancer Diagnostics market restraint impact
  • Fig. 21 Prostate Cancer Diagnostics market strategic initiatives analysis
  • Fig. 22 Prostate Cancer Diagnostics market: Test Type movement analysis
  • Fig. 23 Prostate Cancer Diagnostics market: Test Type outlook and key takeaways
  • Fig. 24 Preliminary Tests Prostate Cancer Diagnostics market estimates and forecast, 2018 - 2030
  • Fig. 25 PSA Tests Prostate Cancer Diagnostics market estimates and forecast, 2018 - 2030
  • Fig. 26 Free PSA Test Prostate Cancer Diagnostics market estimates and forecast, 2018 - 2030
  • Fig. 27 Total PSA Test Prostate Cancer Diagnostics market estimates and forecast, 2018 - 2030
  • Fig. 28 Other Preliminary Tests Prostate Cancer Diagnostics market estimates and forecast, 2018 - 2030
  • Fig. 29 Confirmatory Tests Prostate Cancer Diagnostics market estimates and forecast, 2018 - 2030
  • Fig. 30 Pca3 Test Prostate Cancer Diagnostics market estimates and forecast, 2018 - 2030
  • Fig. 31 Trans-Rectal Ultrasound Prostate Cancer Diagnostics market estimates and forecast, 2018 - 2030
  • Fig. 32 Biopsy Test Prostate Cancer Diagnostics market estimates and forecast, 2018 - 2030
  • Fig. 33 Prostate Cancer Diagnostics Market: Type movement Analysis
  • Fig. 34 Prostate Cancer Diagnostics market: Type outlook and key takeaways
  • Fig. 35 Adenocarcinoma market estimates and forecasts, 2018 - 2030
  • Fig. 36 Interstitial Cell Carcinoma market estimates and forecasts,2018 - 2030
  • Fig. 37 Other market estimates and forecasts,2018 - 2030
  • Fig. 38 Prostate Cancer Diagnostics market: End Use movement analysis
  • Fig. 39 Prostate Cancer Diagnostics market: End Use outlook and key takeaways
  • Fig. 40 Hospitals market estimates and forecasts, 2018 - 2030
  • Fig. 41 Outpatient Facilities market estimates and forecasts,2018 - 2030
  • Fig. 42 Home Care market estimates and forecasts, 2018 - 2030
  • Fig. 43 Research & Manufacturing market estimates and forecasts,2018 - 2030
  • Fig. 44 Global Prostate Cancer Diagnostics market: Regional movement analysis
  • Fig. 45 Global Prostate Cancer Diagnostics market: Regional outlook and key takeaways
  • Fig. 46 Global Prostate Cancer Diagnostics market share and leading players
  • Fig. 47 North America market share and leading players
  • Fig. 48 Europe market share and leading players
  • Fig. 49 Asia Pacific market share and leading players
  • Fig. 50 Latin America market share and leading players
  • Fig. 51 Middle East & Africa market share and leading players
  • Fig. 52 North America: SWOT
  • Fig. 53 Europe SWOT
  • Fig. 54 Asia Pacific SWOT
  • Fig. 55 Latin America SWOT
  • Fig. 56 MEA SWOT
  • Fig. 57 North America, by country
  • Fig. 58 North America
  • Fig. 59 North America market estimates and forecasts, 2018 - 2030
  • Fig. 60 U.S.
  • Fig. 61 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 62 Canada
  • Fig. 63 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 64 Europe
  • Fig. 65 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 66 UK
  • Fig. 67 UK market estimates and forecasts, 2018 - 2030
  • Fig. 68 Germany
  • Fig. 69 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 70 France
  • Fig. 71 France market estimates and forecasts, 2018 - 2030
  • Fig. 72 Italy
  • Fig. 73 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 74 Spain
  • Fig. 75 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 76 Denmark
  • Fig. 77 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 78 Sweden
  • Fig. 79 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 80 Norway
  • Fig. 81 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 82 Asia Pacific
  • Fig. 83 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 84 China
  • Fig. 85 China market estimates and forecasts, 2018 - 2030
  • Fig. 86 Japan
  • Fig. 87 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 88 India
  • Fig. 89 India market estimates and forecasts, 2018 - 2030
  • Fig. 90 Thailand
  • Fig. 91 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 92 South Korea
  • Fig. 93 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 94 Australia
  • Fig. 95 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 96 Latin America
  • Fig. 97 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 98 Brazil
  • Fig. 99 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 100 Mexico
  • Fig. 101 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 102 Argentina
  • Fig. 103 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 104 Middle East and Africa
  • Fig. 105 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 106 South Africa
  • Fig. 107 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 108 Saudi Arabia
  • Fig. 109 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 110 UAE
  • Fig. 111 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 112 Kuwait
  • Fig. 113 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 114 Market share of key market players - Prostate Cancer Diagnostics market